Phase II. Evaluation of 4'- (9-acridinylamino) -methanesulfon-m-anisidide (AMSA) in patients with advanced sarcoma
Sordillo, P.P.; Magill, G.B.; Gralla, R.J.; Golbey, R.B.
Cancer Treatment Reports 64(10-11): 1129-1130
1980
ISSN/ISBN: 0361-5960 PMID: 6893950 Document Number: 158963
Document emailed within 1 workday
Related Documents
Sordillo, P.P.; Helson, L.; Lesser, M. 1980: Evaluation of 4'-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA, NSC 249992) on human tumors in nude mice Cancer Clinical Trials 3(4): 385-389Legha, S.S.; Gutterman, J.U.; Hall, S.W.; Benjamin, R.S.; Burgess, M.A.; Valdivieso, M.; Bodey, G.P. 1978: Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative Cancer Research 38(11 Part 1): 3712-3716
Van Echo, D.A.; Chiuten, D.F.; Gormley, P.E.; Lichtenfeld, J.L.; Scoltock, M.; Wiernik, P.H. 1979: Phase i clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule Cancer Research 39(10): 3881-3884
Del Bino, G.; Darzynkiewicz, Z. 1991: Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells Cancer Research 51(4): 1165-1169
Cysyk, R.L.; Shoemaker, D.; Adamson, R.H. 1977: The pharmacologic disposition of 4'-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats Drug Metabolism and Disposition: the Biological Fate of Chemicals 5(6): 579-590
Hall, S.W.; Friedman, J.; Legha, S.S.; Benjamin, R.S.; Gutterman, J.U.; Loo, T.L. 1983: Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) Cancer Research 43(7): 3422-3426
Gormley, P.E.; Sethi, V.S.; Cysyk, R.L. 1978: Interaction of 4'-(9-acridinylamino)methanesulfon-m-anisidide with DNA and inhibition of oncornavirus reverse transcriptase and cellular nucleic acid polymerases Cancer Research 38(5): 1300-1306
Gralla, R.J.; Sordillo, P.P.; Magill, G.B. 1978: Phase II evaluation of pyrazofurin in patients with metastatic sarcoma Cancer Treatment Reports 62(10): 1573-1574
Currie, V.E.; Camacho, F.; Wittes, R.; Young, C. 1980: Phase Ii evaluation of vindesine in patients with advanced breast cancer Cancer Treatment Reports 64(4-5): 693-695
Mouridsen, H.T.; Bramwell, V.H.; Lacave, J.; Metz, R.; Vendrik, C.; Hild, J.; McCreanney, J.; Sylvester, R. 1981: Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase Ii trial of the EORTC soft tissue and bone sarcoma group Cancer Treatment Reports 65(5-6): 509-511
Creagan, E.T.; Nichols, W.C.; O'Fallon, J.R. 1981: Phase Ii evaluation of PALA in patients with advanced head and neck cancer Cancer Treatment Reports 65(9-10): 827-829
Evans, W.K.; Shepherd, F.A.; Blackstein, M.E.; Osoba, D.; Taylor, D. 1985: Phase Ii evaluation of bisantrene in patients with advanced renal cell carcinoma Cancer Treatment Reports 69(6): 727-728
Amodio, A.; Carpano, S.; Manfredi, C.; Del Monte, G.; Di Lauro, L.; Gionfra, T.; Conti, F.; Paoletti, G.; Lopez, M. 1999: Gemcitabine in advanced stage soft tissue sarcoma: a phase Ii study La Clinica Terapeutica 150(1): 17-20
Kris, M.G.; Kinahan, J.J.; Gralla, R.J.; Fanucchi, M.P.; Wertheim, M.S.; O'Connell, J.P.; Marks, L.D.; Williams, L.; Farag, F.; Young, C.W. 1988: Phase i trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer Cancer Research 48(19): 5573-5579
Carli, M.; Perilongo, G.; di Montezemolo, L.C.; De Bernardi, B.; Ceci, A.; Paolucci, G.; Pianca, C.; Calculli, G.; Di Tullio, M.T.; Grotto, P. 1987: Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group Cancer Treatment Reports 71(5): 525-527
Amrein, P.C.; Coleman, M.; Richards, F.; Poulin, R.F.; Bernhardt, B.; Ginsberg, S.J.; Green, M.R.; Morrison, A.; Cortes, E.; Kiang, D.; Weinberg, V.; Wood, W.C. 1982: Phase Ii study of AMSA in patients with metastatic breast cancer: a Cancer and Leukemia Group B study Cancer Treatment Reports 66(5): 1211-1213
Jehn, U.; Heinemann, V.; Wilmanns, W. 1989: Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML) Anticancer Research 9(1): 119-124
Wagener, D.J.; van Oosterom, A.T.; Mulder, J.H.; Somers, R.; Mouridsen, H.T.; Cortes Funes, H.; Thomas, D.; Sylvester, R. 1986: Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer Cancer Treatment Reports 70(5): 615-618
Stehman, F.B.; Blessing, J.A.; Delgado, G.; Louka, M. 1983: Phase Ii evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma: a Gynecologic Oncology Group Study Cancer Treatment Reports 67(7-8): 737-738
Buesa, J.M.; Mouridsen, H.T.; Santoro, A.; Somers, R.; Bramwell, V.; van Oosterom, A.T.; Wagener, T.; Vendrik, C.; Thomas, D. 1984: Treatment of advanced soft tissue sarcomas with low-dose methotrexate: a phase Ii trial by the European Organization of Research on Treatment for Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Cancer Treatment Reports 68(4): 683-684